Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  06:12 2022-08-15 am EDT
10994.00 GBX   +2.63%
05:39aFTSE 100 up as AstraZeneca gains offset commodity losses
RE
05:30aAstraZeneca Tops FTSE 100 Risers on Drug Progress
DJ
05:08aEuropean shares edge higher on healthcare lift, weak China data stokes worries
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ASTRAZENECA : Credit Suisse maintains a Buy rating

06/07/2022 | 05:27am EDT
share with twitter
share with LinkedIn
share with facebook

Already positive, the research from Credit Suisse and its analyst Matthew Weston still consider the stock as a Buy opportunity. The target price remains set at GBX 11000.


© MarketScreener with dpa-AFX Analyser 2022
All news about ASTRAZENECA PLC
05:39aFTSE 100 up as AstraZeneca gains offset commodity losses
RE
05:30aAstraZeneca Tops FTSE 100 Risers on Drug Progress
DJ
05:08aEuropean shares edge higher on healthcare lift, weak China data stokes worries
RE
05:08aAstraZeneca, Daiichi Sankyo Say Their Breast Cancer Drug Delayed Disease Progression in..
MT
05:07aFTSE 100 Rises as AstraZeneca Gains on Positive Trial Result
DJ
04:42aFTSE 100 up 0.2%, lifted by Astrazeneca
MS
03:53aLONDON STOCK EXCHANGE : FTSE 100 inches higher as AstraZeneca counters China worries
RE
03:46aEUROPE : European shares edge higher; weak China data stokes worries
RE
02:32aAstraZeneca-Daiichi's breast cancer drug improves survival in study
RE
02:28aEnhertu Significantly Delayed Breast Cancer Progression in Trial, AstraZeneca Says
DJ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 198 M - -
Net income 2022 4 471 M - -
Net Debt 2022 24 385 M - -
P/E ratio 2022 46,3x
Yield 2022 2,27%
Capitalization 201 B 201 B -
EV / Sales 2022 5,10x
EV / Sales 2023 4,73x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 129,86 $
Average target price 144,15 $
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC23.44%201 219
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131